--- title: "Acumen Pharmaceuticals (ABOS) news: going concern and offering" url: "https://aibio.space/companies/acumen-pharmaceuticals/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "ABOS going concern and offering news: Acumen Pharmaceuticals files a $500,000,000 shelf registration. Acumen Pharmaceuticals, Inc." --- ABOS Acumen Pharmaceuticals, Inc. NASDAQ · United States # Acumen Pharmaceuticals (ABOS) news ABOS going concern and offering news Financings · 2026-10-26 ## [Acumen Pharmaceuticals files a $500,000,000 shelf registration](https://aibio.space/news/acumen-pharmaceuticals-files-500-000-000-shelf-registration/) The S-3 covers common stock, preferred stock, debt securities and warrants, with pricing and terms to come in later prospectus supplements. Acumen's auditor included a going concern paragraph in its report on the 2025 financial statements. ## Latest Acumen Pharmaceuticals news 1. 2026-03-16 Financings [Acumen Pharmaceuticals agrees to $35.75 million private placement at $3.30 per share](https://aibio.space/news/acumen-pharmaceuticals-agrees-35-75-million-private-placement-3-30/) Acumen Pharmaceuticals, Inc. entered into a securities purchase agreement with institutional and accredited investors. RA Capital Management, an existing investor, led the deal, and the release names no placement agent. 2. 2025-11-13 Financings [Acumen Pharmaceuticals registers $50,000,000 in share sales with three agents](https://aibio.space/news/acumen-pharmaceuticals-registers-50-000-000-share-sales-three-agents/) Acumen has sold $12.3 million of stock under its sales agreement so far, which leaves $37.7 million available. BofA Securities, Stifel and BTIG are the sales agents. ## Acumen Pharmaceuticals at a glance - **Ticker**: ABOS - **Listing**: NASDAQ - **Country**: United States - **Cash, Sep 30, 2026**: $78.6 million ### Related companies - [Oragenics](https://aibio.space/companies/oragenics/) AMEX: OGEN - [Processa Pharmaceuticals](https://aibio.space/companies/processa-pharmaceuticals/) NASDAQ: PCSA - [ABVC BioPharma](https://aibio.space/companies/abvc-biopharma/) NASDAQ: ABVC - [Citius Oncology](https://aibio.space/companies/citius-oncology/) NASDAQ: CTOR - [Journey Medical](https://aibio.space/companies/journey-medical/) NASDAQ: DERM - [Cerenome](https://aibio.space/companies/cerenome/) NASDAQ: CNSY - [CytoDyn](https://aibio.space/companies/cytodyn/) OTC: CYDY - [RISING BIOSCIENCES INC](https://aibio.space/companies/rising-biosciences/) OTC: RBII ### Also on NASDAQ - [Ascendis Pharma](https://aibio.space/companies/ascendis-pharma/) ASND - [Scilex Holding](https://aibio.space/companies/scilex/) SCLX - [SIGA Technologies](https://aibio.space/companies/siga-technologies/) SIGA - [Spruce Biosciences](https://aibio.space/companies/spruce-biosciences/) SPRB - [Tenaya Therapeutics](https://aibio.space/companies/tenaya-therapeutics/) TNYA - [BioMarin Pharmaceutical](https://aibio.space/companies/biomarin-pharmaceutical/) BMRN ## What Acumen Pharmaceuticals does Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company developing a disease-modifying approach aimed at what it believes is a key underlying cause of Alzheimer's disease (AD). The company focuses on soluble amyloid-beta oligomers (AβOs), which it describes as a primary toxin in AD pathology. Its lead candidate, sabirnetug (ACU193), is a recombinant humanized IgG2 monoclonal antibody designed to selectively target AβOs. Sabirnetug is in the Phase 2 ALTITUDE-AD trial, a randomized, double-blind, placebo-controlled study of 542 participants with mild cognitive impairment or mild dementia due to AD, with top-line results expected in late 2026. The Phase 1 INTERCEPT-AD trial in early AD was completed in the second quarter of 2023. The company is also developing a blood-brain barrier-penetrating, AβO-targeted Enhanced Brain Delivery (EBD) therapy under a July 2025 collaboration with JCR Pharmaceuticals, with an IND targeted for mid-2027. A subcutaneous formulation of sabirnetug is being developed under a global collaboration with Halozyme, Inc. | Product or program | What it is | Stage | |---|---|---| | Sabirnetug (ACU193) | Anti-AβO antibody for mild cognitive impairment or mild dementia due to Alzheimer's disease | Phase 2 ALTITUDE-AD; top-line results expected late 2026 | | Sabirnetug subcutaneous | Subcutaneous formulation of sabirnetug developed with Halozyme | Phase 1 results announced March 2025 | | EBD therapy | Blood-brain barrier-penetrating AβO-targeted therapy developed with JCR | Preclinical; IND targeted for mid-2027 | Summarised from the company's [10-K filed Mar 26, 2026](https://www.sec.gov/Archives/edgar/data/1576885/000162828026021413/abos-20251231.htm). ## Acumen Pharmaceuticals annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$104.9 million](https://www.sec.gov/Archives/edgar/data/1576885/000162828026021413/) | [$93.8 million](https://www.sec.gov/Archives/edgar/data/1576885/000162828026021413/) | | Net income (loss) | [-$121.3 million](https://www.sec.gov/Archives/edgar/data/1576885/000162828026021413/) | [-$102.3 million](https://www.sec.gov/Archives/edgar/data/1576885/000162828026021413/) | | Cash from operations | [-$115.5 million](https://www.sec.gov/Archives/edgar/data/1576885/000162828026021413/) | [-$86.2 million](https://www.sec.gov/Archives/edgar/data/1576885/000162828026021413/) | | Cash and equivalents | [$54.0 million](https://www.sec.gov/Archives/edgar/data/1576885/000162828026067276/) | [$35.6 million](https://www.sec.gov/Archives/edgar/data/1576885/000162828026021413/) | | Short-term investments | [$62.9 million](https://www.sec.gov/Archives/edgar/data/1576885/000162828026067276/) | [$135.9 million](https://www.sec.gov/Archives/edgar/data/1576885/000162828026021413/) | Latest balance sheet, Sep 30, 2026 (10-Q): cash and equivalents $53.1 million, plus short-term investments of $25.5 million, $78.6 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Acumen Pharmaceuticals Has Acumen Pharmaceuticals issued a going-concern warning? Our latest story on this, dated Oct 26, 2026: "Acumen Pharmaceuticals files a $500,000,000 shelf registration". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/acumen-pharmaceuticals-files-500-000-000-shelf-registration/). Has Acumen Pharmaceuticals raised money recently? Our latest story on this, dated Mar 16, 2026: "Acumen Pharmaceuticals agrees to $35.75 million private placement at $3.30 per share". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/acumen-pharmaceuticals-agrees-35-75-million-private-placement-3-30/). What is the ticker symbol of Acumen Pharmaceuticals? Acumen Pharmaceuticals, Inc. trades under the ticker ABOS on NASDAQ. Where is Acumen Pharmaceuticals listed? Acumen Pharmaceuticals, Inc. is listed on NASDAQ. What is the SEC CIK of Acumen Pharmaceuticals? The SEC Central Index Key (CIK) for Acumen Pharmaceuticals, Inc. is 1576885. Its filings are on SEC EDGAR. How many shares does Acumen Pharmaceuticals have outstanding? 72,317,285 shares as of 2026-08-07, per the cover page of its 10-Q filed 2026-08-12. Which country or territory is Acumen Pharmaceuticals listed under? Our directory records Acumen Pharmaceuticals, Inc. under United States. What does Acumen Pharmaceuticals do? Our directory classifies Acumen Pharmaceuticals, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Acumen Pharmaceuticals? The ISIN recorded for Acumen Pharmaceuticals, Inc. is US00509G2093. Does aibio.space cover Acumen Pharmaceuticals? aibio.space lists Acumen Pharmaceuticals, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Acumen Pharmaceuticals incorporated? SEC records list its state or country of incorporation as DE. What does Acumen Pharmaceuticals develop? Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company developing a disease-modifying approach aimed at what it believes is a key underlying cause of Alzheimer's disease (AD). The company focuses on soluble amyloid-beta oligomers (AβOs), which it describes as a primary toxin in AD pathology. What is Sabirnetug (ACU193) from Acumen Pharmaceuticals? Sabirnetug (ACU193): Anti-AβO antibody for mild cognitive impairment or mild dementia due to Alzheimer's disease Stage: Phase 2 ALTITUDE-AD; top-line results expected late 2026. What is Sabirnetug subcutaneous from Acumen Pharmaceuticals? Sabirnetug subcutaneous: Subcutaneous formulation of sabirnetug developed with Halozyme Stage: Phase 1 results announced March 2025. Is Acumen Pharmaceuticals profitable? Acumen Pharmaceuticals, Inc. reported a net loss of $121.3 million for the fiscal year ended Dec 31, 2025, and used $115.5 million of cash in operations, per its annual report to the SEC. ## Investor discussion: Acumen Pharmaceuticals Members talk about Acumen Pharmaceuticals (ABOS). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Acumen Pharmaceuticals, newest first. Each line links the filing it comes from. 1. 2026-10-26 Financings Set up an at-the-market program to sell shares over time. SEC Form S-3. [Source](https://www.sec.gov/Archives/edgar/data/1576885/000162828026067291/acumenpharmaceuticals-sx3.htm) 2. 2026-03-26 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1576885/000162828026021413/abos-20251231.htm) 3. 2026-03-16 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1576885/000162828026017885/ex991active_168579885x14xa.htm) 4. 2025-11-13 Financings Set up an at-the-market program to sell shares over time. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1576885/000162828025051852/acumen-424b5.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:ABOS on TradingView](https://www.tradingview.com/symbols/NASDAQ-ABOS/). ## SEC filings and registration - **SEC name**: Acumen Pharmaceuticals, Inc. - **CIK**: 1576885 - **Industry (SIC)**: Biological Products, (No Diagnostic Substances) (2836) - **US tickers**: ABOS (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**:
Emerging growth company - **Business address**: 1210-1220 WASHINGTON STREET, NEWTON, MA, 02465 - **Phone**: 617-344-4190 - **Shares outstanding**: 72,317,285 as of 2026-08-07 (10-Q filed 2026-08-12) ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1576885/000162828026062137/abos-20260916.htm) filed 2026-09-16 - [10-Q](https://www.sec.gov/Archives/edgar/data/1576885/000162828026056199/abos-20260630.htm) filed 2026-08-12 - [8-K](https://www.sec.gov/Archives/edgar/data/1576885/000162828026055940/abos-20260812.htm) filed 2026-08-12 - [8-K](https://www.sec.gov/Archives/edgar/data/1576885/000162828026043416/abos-20260612.htm) filed 2026-06-16 - [8-K](https://www.sec.gov/Archives/edgar/data/1576885/000162828026040447/abos-20260603.htm) filed 2026-06-03 - [10-Q](https://www.sec.gov/Archives/edgar/data/1576885/000162828026034204/abos-20260331.htm) filed 2026-05-12 - [8-K](https://www.sec.gov/Archives/edgar/data/1576885/000162828026033868/abos-20260512.htm) filed 2026-05-12 - [DEF 14A](https://www.sec.gov/Archives/edgar/data/1576885/000162828026026870/abos-20260423.htm) filed 2026-04-23 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001576885), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Acumen Pharmaceuticals, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker ABOS, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Acumen Pharmaceuticals, Inc. - **Ticker**: ABOS - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: US00509G2093 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-ABOS/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/acumen-pharmaceuticals/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Acumen Pharmaceuticals (ABOS) news: going concern and offering", 2026-10-31, https://aibio.space/companies/acumen-pharmaceuticals/